Publications

1. Ahn DH, Ridinger M, Cannon TL, Mendelsohn L, Starr JS, Hubbard JM, Kasi A, Barzi A, Samuelsz E, Karki A, Subramanian RA, Yemane D, Kim R, Wu CC, Croucher PJP, Smeal T, Kabbinavar FF, Lenz HJ. Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. J Clin Oncol. 2024 Oct 30; JCO2401266 [Epub ahead of print]
   View PubMed
2. Eslinger C, Wu C, Ahn DH. Minimal residual disease monitoring via ctDNA: a case report of Lynch syndrome with synchronous colorectal cancer and review of literature. J Gastrointest Oncol. 2024 Jun 30; 15 (3):1341-1347 Epub 2024 June 19
   View PubMed
3. Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klumpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Komatsu Y, Ahn DH, Epstein RS, Halim AB, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA, FOENIX-CCA2 Study Investigators. Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer. Future Oncol. 2024 Jun 17; 1-12 Epub 2024 June 17
   View PubMed
4. Ahn DH, Barzi A, Ridinger M, Samuelsz E, Subramanian RA, Croucher PJP, Smeal T, Kabbinavar FF, Lenz HJ. Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. Clin Cancer Res. 2024 May 15; 30 (10):2039-2047
   View PubMed
5. Desai A, Xiao AH, Choi D, Toruner MD, Walden D, Halfdanarson TR, Alberts S, McWilliams RR, Mahipal A, Ahn D, Babiker H, Stybayeva G, Revzin A, Kizilbash S, Adjei A, Bekaii-Saab T, Mansfield AS, Carr RM, Ma WW. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2024 May 13; 16 (10)
   View PubMed
6. Elhariri A, Alhaj A, Ahn D, Sonbol MB, Bekaii-Saab T, Wu C, Rutenberg MS, Stauffer J, Starr J, Majeed U, Jones J, Borad M, Babiker H. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. World J Clin Oncol. 2023 Aug 24; 14 (8):285-296
   View PubMed
7. Ou FS, Ahn DH, Dixon JG, Grothey A, Lou Y, Kasi PM, Hubbard JM, Van Cutsem E, Saltz LB, Schmoll HJ, Goldberg RM, Venook AP, Hoff P, Douillard JY, Hecht JR, Hurwitz H, Punt CJA, Koopman M, Bokemeyer C, Fuchs CS, Diaz-Rubio E, Tebbutt NC, Cremolini C, Kabbinavar FF, Bekaii-Saab T, Chibaudel B, Yoshino T, Zalcberg J, Adams RA, de Gramont A, Shi Q. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database. Cancers (Basel). 2023 Aug 15; 15 (16)
   View PubMed
8. Ou FS, Walden DJ, Larson JJ, Kang S, Griswold CR, Ueberroth BE, Patel B, Draper A, Raman P, Alese OB, Sonbol MB, Bekaii-Saab TS, Wu CS, Ahn DH. Changes in Prescribing Patterns in Stage III Colon Cancer. J Natl Compr Canc Netw. 2023 Aug; 21 (8):841-850.e4
   View PubMed
9. Borad MJ, Bai LY, Richards D, Mody K, Hubbard J, Rha SY, Soong J, McCormick D, Tse E, O'Brien D, Bayat A, Ahn D, Davis SL, Park JO, Oh DY. Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study. Hepatology. 2023 Mar 1; 77 (3):760-773 Epub 2023 Feb 17
   View PubMed
10. Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klumpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA, FOENIX-CCA2 Study Investigators. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med. 2023 Jan 19; 388 (3):228-239
    View PubMed
11. Sonbol MB, Siddiqi R, Uson PLS, Pathak S, Firwana B, Botrus G, Almader-Douglas D, Ahn DH, Borad MJ, Starr J, Jones J, Stucky CC, Smoot R, Riaz IB, Bekaii-Saab T. The Role of Systemic Therapy in Resectable Colorectal Liver Metastases: Systematic Review and Network Meta-Analysis. Oncologist. 2022 Dec 9; 27 (12):1034-1040
    View PubMed
12. Uson PLS Jr, Kunze KL, Golafshar MA, Botrus G, Riegert-Johnson D, Boardman L, Borad MJ, Ahn D, Sonbol MB, Kahn A, Klint M, Esplin ED, Nussbaum RL, Stewart AK, Bekaii-Saab T, Samadder NJ. Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study. Dig Dis Sci. 2022 Nov; 67 (11):5107-5115 Epub 2022 Feb 05
    View PubMed
13. Storandt MH, Gile JJ, Palmer ME, Zemla TJ, Ahn DH, Bekaii-Saab TS, Jin Z, Tran NH, Mahipal A. Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma. Cancers (Basel). 2022 Oct 22; 14 (21)
    View PubMed
14. Ahn DH, Bekaii-Saab T. The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer. JAMA Oncol 2022 Sep 1; 8 (9):1257-1259
    View PubMed
15. Ahn D, Sidel M, Panattoni L, Sacks N, Hernandez J, Villacorta R. Real-world outcomes in patients with first-line and second-line therapy for advanced esophageal squamous cell carcinoma. Future Oncol. 2022 Sep; 18 (30):3419-3433 Epub 2022 Sept 13
    View PubMed
16. Uson Junior PLS, DeLeon TT, Bogenberger JM, Pai RK, Kosiorek HE, Yin J, Ahn DH, Sonbol MB, Bekaii-Saab T, Mansfield AS, Buetow K, Gores GJ, Smoot R, Vasmatzis G, Kipp BR, Mahipal A, Baker AT, Babiker H, Barro O, Dumbauld C, Zhou Y, Aslam FN, Barrett M, Jacobs B, Meurice N, Arora M, Petit J, Elliott N, Nagalo B, Salomao MA, Borad MJ. FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. Dig Dis Sci. 2022 Aug; 67(8):3797-3805. Epub 2021 Nov 13.
    View PubMed
17. Palmer CD, Rappaport AR, Davis MJ, Hart MG, Scallan CD, Hong SJ, Gitlin L, Kraemer LD, Kounlavouth S, Yang A, Smith L, Schenk D, Skoberne M, Taquechel K, Marrali M, Jaroslavsky JR, Nganje CN, Maloney E, Zhou R, Navarro-Gomez D, Greene AC, Grotenbreg G, Greer R, Blair W, Cao MD, Chan S, Bae K, Spira AI, Roychowdhury S, Carbone DP, Henick BS, Drake CG, Solomon BJ, Ahn DH, Mahipal A, Maron SB, Johnson B, Rousseau R, Yelensky R, Liao CY, Catenacci DVT, Allen A, Ferguson AR, Jooss K. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2022 Aug; 28 (8):1619-1629 Epub 2022 Aug 15
    View PubMed
18. Zhu M, Chen C, Foster NR, Hartley C, Mounajjed T, Salomao MA, Fruth BF, Beamer SE, Kim Y, Harrington SM, Pitot HC, Sanhueza CT, Feng Y, Herrmann J, McWilliams RR, Lucien F, Huang BQ, Ma WW, Bekaii-Saab TS, Dong H, Wigle D, Ahn DH, Hallemeier CL, Blackmon S, Yoon HH. Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction. Clin Cancer Res. 2022 Jul 15; 28 (14):3021-3031
    View PubMed
19. Uson Junior PLS, Majeed U, Yin J, Botrus G, Sonbol MB, Ahn DH, Starr JS, Jones JC, Babiker H, Inabinett SR, Wylie N, Boyle AWR, Bekaii-Saab TS, Gores GJ, Smoot R, Barrett M, Nagalo B, Meurice N, Elliott N, Petit J, Zhou Y, Arora M, Dumbauld C, Barro O, Baker A, Bogenberger J, Buetow K, Mansfield A, Mody K, Borad MJ. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. JCO Precis Oncol. 2022 Jun; 6 (1):e2100274
    View PubMed
20. Ahn D, Walden D, Bekaii-Saab T. Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer. Expert Opin Investig Drugs. 2022 May; 31 (5):437-441 Epub 2022 Mar 17
    View PubMed
21. Uson PLS Jr, Riegert-Johnson D, Boardman L, Kisiel J, Mountjoy L, Patel N, Lizaola-Mayo B, Borad MJ, Ahn D, Sonbol MB, Jones J, Leighton JA, Gurudu S, Singh H, Klint M, Kunze KL, Golafshar MA, Esplin ED, Nussbaum RL, Stewart AK, Bekaii-Saab TS, Jewel Samadder N. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study. Clin Gastroenterol Hepatol. 2022 Mar; 20 (3):e508-e528 Epub 2021 Apr 20
    View PubMed
22. Laughlin BS, Petersen MM, Yu NY, Anderson JD, Rule WG, Borad MJ, Aqel BA, Sonbol MB, Mathur AK, Moss AA, Bekaii-Saab TS, Ahn DH, DeWees TA, Sio TT, Ashman JB. Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies: a single-center experience. J Gastrointest Oncol. 2022 Feb; 13 (1):288-297
    View PubMed
23. Uson Junior PL, Kunze KL, Golafshar MA, Riegert-Johnson D, Boardman L, Borad MJ, Ahn D, Sonbol MB, Faigel DO, Fukami N, Pannala R, Barrus K, Mountjoy L, Esplin ED, Nussbaum RL, Stewart AK, Bekaii-Saab T, Samadder NJ. Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study. Cancer Prev Res (Phila). 2022 Feb; 15 (2):121-128 Epub 2021 Nov 15
    View PubMed
24. Ahn DH, Uson Junior PLS, Masci P, Kosiorek H, Halfdanarson TR, Mody K, Babiker H, DeLeon T, Sonbol MB, Gores G, Smoot R, Bekaii-Saab T, Mahipal A, Mansfield A, Tran NH, Hubbard JM, Borad MJ. A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. Invest New Drugs. 2022 Feb; 40 (1):134-141 Epub 2021 Aug 31
    View PubMed
25. Wintheiser G, Zemla T, Shi Q, Tran N, Prasai K, Tella SH, Mody K, Ahn D, Borad M, Bekaii-Saab T, Mahipal A. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. JCO Precis Oncol. 2022 Jan; 6:e2100156
    View PubMed
26. Arora M, Bogenberger JM, Abdelrahman AM, Yonkus J, Alva-Ruiz R, Leiting JL, Chen X, Serrano Uson Junior PL, Dumbauld CR, Baker AT, Gamb SI, Egan JB, Zhou Y, Nagalo BM, Meurice N, Eskelinen EL, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Buetow KH, Sonbol MB, Mansfield AS, Roberts LR, Bekaii-Saab TS, Ahn DH, Truty MJ, Borad MJ. Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers. Hepatology. 2022 Jan; 75 (1):43-58 Epub 2021 Dec 12
    View PubMed
27. Uson PLS Jr, Samadder NJ, Riegert-Johnson D, Boardman L, Borad MJ, Ahn D, Sonbol MB, Faigel DO, Fukami N, Pannala R, Kunze K, Golafshar M, Klint M, Esplin ED, Nussbaum RL, Stewart AK, Bekaii-Saab T. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. Clin Transl Gastroenterol. 2021 Oct 8; 12 (10):e00414 Epub 2021 Oct 08
    View PubMed
28. Sahin IH, Goyal S, Pumpalova Y, Sonbol MB, Das S, Haraldsdottir S, Ahn D, Ciombor KK, Chen Z, Draper A, Berlin J, Bekaii-Saab T, Lesinski GB, El-Rayes BF, Wu C. Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. Oncologist. 2021 Aug; 26 (8):668-675 Epub 2021 Mar 22
    View PubMed
29. Botrus G, Kosirorek H, Sonbol MB, Kusne Y, Uson Junior PLS, Borad MJ, Ahn DH, Kasi PM, Drusbosky LM, Dada H, Surapaneni PK, Starr J, Ritter A, McMillan J, Wylie N, Mody K, Bekaii-Saab TS. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. Oncologist. 2021 Jul; 26 (7):569-578 Epub 2021 Mar 05
    View PubMed
30. Jatoi A, Ou FS, Ahn DH, Zemla TJ, Le-Rademacher JG, Boland P, Ciombor KK, Jacobs NL, Pasche B, Cleary JM, McCune JS, Pedersen KS, Barzi A, Chiorean EG, Heying EN, Lenz HJ, Sloan JA, Grothey A, Lacouture ME, Bekaii-Saab T. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. Oncologist. 2021 Jul; 26 (7):610-618 Epub 2021 Mar 06
    View PubMed
31. Uson Junior PLS, Nagalo BM, Ahn DH, Bekaii-Saab T, Borad MJ. Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently? Semin Liver Dis. 2021 May; 41 (2):136-141 Epub 2021 May 06
    View PubMed
32. Botrus G, Uson Junior PLS, Raman P, Kaufman AE, Kosiorek H, Yin J, Fu Y, Majeed U, Sonbol MB, Ahn DH, Chang IW, Drusbosky LM, Dada H, Starr J, Borad M, Mody K, Bekaii-Saab TS. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Front Oncol. 2021; 11:794009 Epub 2022 Jan 10
    View PubMed
33. Lieu C, Ahn D. MRD and decision-making in early-stage colorectal cancer Oncology (08909091). 2021; 35 (8):501-3
    
34. Walden D, Sonbol MB, Buckner Petty S, Yoon HH, Borad M, Bekaii-Saab TS, Ahn DH. Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis. Front Oncol. 2021; 11:641044 Epub 2021 Sept 10
    View PubMed
35. Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, Shah S, Almader-Douglas D, Uson Junior PLS, Mahipal A, Ma WW, Jin Z, Mody K, Starr J, Borad MJ, Ahn DH, Murad MH, Bekaii-Saab T. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2020 Dec 1; 6 (12):e204930 Epub 2020 Dec 10
    View PubMed
36. Bhangoo RS, DeWees TA, Yu NY, Ding JX, Liu C, Golafshar MA, Rule WG, Vora SA, Ross HJ, Ahn DH, Beamer SE, Jaroszewski DE, Hallemeier CL, Liu W, Ashman JB, Sio TT. Acute Toxicities and Short-Term Patient Outcomes After Intensity-Modulated Proton Beam Radiation Therapy or Intensity-Modulated Photon Radiation Therapy for Esophageal Carcinoma: A Mayo Clinic Experience. Adv Radiat Oncol. 2020 Sep-Oct; 5 (5):871-879 Epub 2020 May 19
    View PubMed
37. Zhu M, Sonbol MB, Bassam Sonbol M, Halfdanarson T, Hobday T, Ahn D, Ma WW, Bekaii-Saab T. Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. Oncologist. 2020 Aug; 25 (8):e1246-e1248 Epub 2020 July 01
    View PubMed
38. Almquist DR, Ahn DH, Bekaii-Saab TS. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. BioDrugs. 2020 Jun; 34 (3):349-362
    View PubMed
39. Chakrabarti S, Zemla TJ, Ahn DH, Ou FS, Fruth B, Borad MJ, Hartgers ML, Wessling J, Walkes RL, Alberts SR, McWilliams RR, Liu MC, Durgin LM, Bekaii-Saab TS, Mahipal A. Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. Oncologist. 2020 May; 25 (5):380-e763 Epub 2019 Dec 11
    View PubMed
40. Sonbol MB, Mountjoy LJ, Firwana B, Liu AJ, Almader-Douglas D, Mody K, Hubbard J, Borad M, Ahn DH, Murad MH, Bekaii-Saab T. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials. JAMA Oncol. 2020 Mar 1; 6 (3):e194489 Epub 2020 Mar 12
    View PubMed
41. Barzi A, Miksad R, Surinach A, Corvino FA, Wang S, Torres AZ, Mamlouk K, Pulgar S, Valderrama A, Bekaii-Saab T, Ahn D. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. Pancreas. 2020 Feb; 49 (2):193-200
    View PubMed
42. Ahn DH, Bekaii-Saab T. Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors. Chin Clin Oncol. 2020 Feb; 9 (1):6 Epub 2020 Feb 20
    View PubMed
43. Mody K, Kasi PM, Yang J, Surapaneni PK, Bekaii-Saab T, Ahn DH, Mahipal A, Sonbol MB, Starr JS, Roberts A, Nagy R, Lanman R, Borad MJ. Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers. JCO Precis Oncol. 2019 Dec; 3:1-9
    View PubMed
44. Ahn DH, Bekaii-Saab T. AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): ready for prime time? Chin Clin Oncol 2019 Oct; 8 (S1):S19 Epub 2019 May 06
    View PubMed
45. Sonbol MB, Benkhadra R, Wang Z, Firwana B, Walden DJ, Mody K, Hubbard JM, Murad MH, Ahn DH, Bekaii-Saab T. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. Oncologist. 2019 Sep; 24 (9):1174-1179 Epub 2019 June 04
    View PubMed
46. Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Aug; 20 (8):1070-1082 Epub 2019 June 28
    View PubMed
47. Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg M, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. Clin Cancer Res. 2019 Jun 15; 25(12):3495-3507. Epub 2019 Feb 25.
    View PubMed
48. Arsanjani R, Agasthi P, Ahn DH, Mookadam F, Yang M. Metastatic Neuroendocrine Tumor with Cardiac Involvement Utilizing Multi-Modality Imaging. Korean Circ J. 2019 Jun; 49 (6):557-558 Epub 2019 Apr 04
    View PubMed
49. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jun 1; 5 (6):824-830
    View PubMed
50. Sonbol MB, Ahn DH, Goldstein D, Okusaka T, Tabernero J, Macarulla T, Reni M, Li CP, O'Neil B, Van Cutsem E, Bekaii-Saab T. CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. Future Oncol. 2019 Apr; 15 (12):1295-1302 Epub 2019 Feb 15
    View PubMed
51. Sonbol MB, Ahn DH, Bekaii-Saab T. Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies. Biomedicines. 2019 Mar 10; 7 (1)
    View PubMed
52. Ahn DH, Bekaii-Saab T. Watch and Wait in Rectal Cancer: Who's In and Who's Out? J Oncol Pract 2019 Mar; 15 (3):133-134
    View PubMed
53. Ramsey ML, Talbert E, Ahn D, Bekaii-Saab T, Badi N, Bloomston PM, Conwell DL, Cruz-Monserrate Z, Dillhoff M, Farren MR, Hinton A, Krishna SG, Lesinski GB, Mace T, Manilchuk A, Noonan A, Pawlik TM, Rajasekera PV, Schmidt C, Guttridge D, Hart PA. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Pancreatology. 2019 Jan; 19 (1):80-87 Epub 2018 Nov 10
    View PubMed
54. Finn RS, Ahn DH, Javle MM, Tan BR Jr, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Chavira R, Christy-Bittel J, Barrett E, Sawyer MB, Bekaii-Saab TS. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. Invest New Drugs. 2018 Dec; 36 (6):1037-1043 Epub 2018 May 22
    View PubMed
55. Jain A, Borad MJ, Kelley RK, Wang Y, Abdel-Wahab R, Meric-Bernstam F, Baggerly KA, Kaseb AO, Al-Shamsi HO, Ahn DH, DeLeon T, Bocobo AG, Bekaii-Saab T, Shroff RT, Javle M. Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. JCO Precis Oncol. 2018 Nov; 2:1-12
    View PubMed
56. Ahn D, Barzi A, Miksad RA, Surinach A, Corvino FA, Valderrama A, Mamlouk K, Pulgar S, Bekaii-Saab T. Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics. Ann Oncol. 2018 Oct; 29 Suppl 8:viii251
    View PubMed
57. DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ. Novel immunotherapy strategies for hepatobiliary cancers. Immunotherapy. 2018 Sep; 10 (12):1077-1091
    View PubMed
58. Weidner TK, Kidwell JT, Glasgow AE, Menias CO, Ahn DH, Pai RK, Heigh RI, Mishra N. Small Intestine Neuroendocrine Tumor in a Patient With MUTYH Adenomatous Polyposis-Case Report and SEER Analysis. Clin Colorectal Cancer. 2018 Sep; 17 (3):e545-e548 Epub 2018 May 09
    View PubMed
59. Ahn DH, Ramanathan RK, Bekaii-Saab T. Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. Cancers (Basel). 2018 Jun 11; 10 (6) Epub 2018 June 11
    View PubMed
60. Meric-Bernstam F, Arkenau H, Tran B, Bahleda R, Kelley R, Hierro C, Ahn D, Zhu A, Javle M, Winkler R, He H, Huang J, Goyal L. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. Ann Oncol. 2018 Jun; 29 Suppl 5:v100 Epub 2020 Jan 07
    View PubMed
61. Bekaii-Saab T, Ou F, Anderson D, Ahn D, Boland P, Ciombor K, Jacobs N, Desnoyers R, Cleary J, Meyers J, Chiorean E, Pedersen K, Barzi A, Sloan J, McCune J, Lacouture M, Lenz H, Grothey A. Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study. Ann Oncol. 2018 Jun; 29 Suppl 5:v105 Epub 2020 Jan 07
    View PubMed
62. Ahn DH, Reardon J, Ahn CW, Bupathi M, Mikhail S, Wu CS, Bekaii-Saab T. Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. Int J Cancer. 2018 Apr 15; 142 (8):1671-1675 Epub 2017 Nov 17
    View PubMed
63. Ahn DH, Bekaii-Saab TS. Genetic Diversity and Treatment Implications in Gastric and Gastroesophageal Cancers: One Size Does Not Fit All. J Oncol Pract 2018 Apr; 14 (4):227-228
    View PubMed
64. DeLeon TT, Ahn DH, Bogenberger JM, Anastasiadis PZ, Arora M, Ramanathan RK, Aqel BA, Vasmatzis G, Truty MJ, Oklu R, Bekaii-Saab TS, Borad MJ. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. Future Oncol. 2018 Mar; 14 (6):553-566 Epub 2018 Feb 20
    View PubMed
65. Bogenberger JM, DeLeon TT, Arora M, Ahn DH, Borad MJ. Emerging role of precision medicine in biliary tract cancers. NPJ Precis Oncol. 2018; 2:21 Epub 2018 Oct 03
    View PubMed
66. Ahn DH, Wu C, Wei L, Williams TM, Wuthrick E, Abdel-Misih S, Harzman A, Husain S, Schmidt C, Goldberg RM, Bekaii-Saab T. The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol. 2017 Dec; 40(6):531-534.
    View PubMed
67. Ahn DH, Ramanathan RK. Targeting the stroma in pancreatic cancer. Chin Clin Oncol. 2017 Dec; 6 (6):65
    View PubMed
68. Sonbol MB, Firwana B, Wang Z, Almader-Douglas D, Borad MJ, Makhoul I, Ramanathan RK, Ahn DH, Bekaii-Saab T. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Cancer. 2017 Dec 1; 123 (23):4680-4686 Epub 2017 Aug 17
    View PubMed
69. Ahn DH, Grothey A. Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers. Lancet Oncol 2017 Nov; 18 (11):1427-1428 Epub 2017 Sept 25
    View PubMed
70. Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist. 2017 Jul; 22 (7):804-810 Epub 2017 May 09
    View PubMed
71. Ahn DH, Bekaii-Saab T. Response to Drs Von Hoff and Renschler. Ther Adv Med Oncol. 2017 Jun; 9 (6):445-446 Epub 2017 May 30
    View PubMed
72. Yang J, Farren MR, Ahn D, Bekaii-Saab T, Lesinski GB. Signaling pathways as therapeutic targets in biliary tract cancer. Expert Opin Ther Targets. 2017 May; 21 (5):485-498 Epub 2017 Mar 17
    View PubMed
73. Ahn DH, Bekaii-Saab T. Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. J Gastrointest Oncol. 2017 Apr; 8 (2):293-301
    View PubMed
74. Bupathi M, Ahn DH, Bekaii-Saab T. Therapeutic options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017 Apr; 6 (2):91-100
    View PubMed
75. Ahn DH, Bekaii-Saab T. The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. Biomedicines. 2017 Mar 4; 5 (1) Epub 2017 Mar 04
    View PubMed
76. Ahn DH, Krishna K, Blazer M, Reardon J, Wei L, Wu C, Ciombor KK, Noonan AM, Mikhail S, Bekaii-Saab T. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. Ther Adv Med Oncol. 2017 Feb; 9 (2):75-82 Epub 2016 Nov 02
    View PubMed
77. Yokoda R, Nagalo BM, Arora M, Egan JB, Bogenberger JM, DeLeon TT, Zhou Y, Ahn DH, Borad MJ. Oncolytic virotherapy in upper gastrointestinal tract cancers. Oncolytic Virother. 2017; 7:13-24 Epub 2018 Mar 23
    View PubMed
78. Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016 Dec 15; 122 (24):3838-3847 Epub 2016 Sept 13
    View PubMed
79. Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM, Ciombor K, Wu C, Shroff RT, Chen JL, Bekaii-Saab T. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer. 2016 Dec 1; 122 (23):3657-3666 Epub 2016 Aug 06
    View PubMed
80. Ahn DH, Ciombor KK, Mikhail S, Bekaii-Saab T. Genomic diversity of colorectal cancer: Changing landscape and emerging targets. World J Gastroenterol. 2016 Jul 7; 22 (25):5668-77
    View PubMed
81. Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther. 2016 Jun; 24 (6):1150-1158 Epub 2016 Apr 04
    View PubMed
82. Farren MR, Mace TA, Geyer S, Mikhail S, Wu C, Ciombor K, Tahiri S, Ahn D, Noonan AM, Villalona-Calero M, Bekaii-Saab T, Lesinski GB. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Clin Cancer Res. 2016 May 15; 22(10):2565-74. Epub 2015 Dec 30.
    View PubMed
83. Bupathi M, Ahn DH, Wu C, Ciombor KK, Stephens JA, Reardon J, Goldstein DA, Bekaii-Saab T. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. Med Oncol. 2016 Apr; 33(4):37. Epub 2016 Mar 19.
    View PubMed
84. Ahn DH, Ozer HG, Hancioglu B, Lesinski GB, Timmers C, Bekaii-Saab T. Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors. Oncotarget. 2016 Feb 02; 7: (5)5306-12.
    View PubMed
85. Ahn DH, Goldberg RM. Colorectal clinical trials: what is on the horizon? Future Oncol. 2016 Feb; 12: (4)525-31.
    View PubMed
86. Ahn DH, Bekaii-Saab T. Adjuvant chemotherapy for rectal cancer after neoadjuvant treatment: FOLFOX, 5-FU, or observation Current Colorectal Cancer Reports. 2016; 12: (5)260-5.
    
87. Ahn DH, Williams TM, Goldstein DA, El-Rayes B, Bekaii-Saab T. Adjuvant therapy for pancreas cancer in an era of value based cancer care. Cancer Treat Rev. 2016 Jan; 42: 10-7.
    View PubMed
88. Bupathi M, Ahn DH, Bekaii-Saab T. Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. Gastrointest Cancer. 2016; 6:21-30.
    View PubMed
89. Ahn DH, Li J, Wei L, Doyle A, Marshall JL, Schaaf LJ, Phelps MA, Villalona-Calero MA, Bekaii-Saab T. Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. Sci Rep. 2015 Jul 10; 5:12122.
    View PubMed
90. Malhotra L, Ahn D, Bloomston M. The Pathogenesis, Diagnosis, and Management of Pancreatic Cancer J Gastrointest Dig Syst .2015;5:278.
    
91. Ahn DH, Ko AH, Meropol NJ, Bekaii-Saab TS. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. Am Soc Clin Oncol Educ Book. 2015; e222-7.
    View PubMed
92. Ahn DH, Bekaii-Saab T. Ampullary cancer: an overview. Am Soc Clin Oncol Educ Book. 2014; 112-5.
    View PubMed
93. Ahn DH, Mehta N, Yorio JT, Xie Y, Yan J, Gerber DE. Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer. Clin Lung Cancer. 2013 Nov; 14: (6)644-50.
    View PubMed
94. Gerber DE, Dahlberg SE, Sandler AB, Ahn D, Schiller JH, Brahmer JR, Johnson DH. Baseline tumour measurements predict survival in advanced non-small cell lung cancer. Br J Cancer. 2013 Sep 17; 109: (6)1476-81.
    View PubMed
95. Ahn DH, Illum HB, Wang DH, Sharma A, Dowell JE. Upper extremity venous thrombosis in patients with cancer with peripherally inserted central venous catheters: a retrospective analysis of risk factors. J Oncol Pract. 2013 Jan; 9: (1)e8-12.
    View PubMed
96. Ahn D, Brickner ME, Dowell J. Embolic stroke secondary to an indwelling catheter in a patient with a patent foramen ovale: a case report and review of the literature. Clin Adv Hematol Oncol. 2012 May; 10: (5)335-7.
    View PubMed
97. Guturu P, Sagi SV, Ahn D, Jaganmohan S, Kuo YF, Sood GK. Capsule endoscopy with PILLCAM ESO for detecting esophageal varices: a meta-analysis. Minerva Gastroenterol Dietol. 2011 Mar; 57: (1)1-11.
    View PubMed
98. Ahn D, Guturu P. Meta-analysis of capsule endoscopy in patients diagnosed or suspected with esophageal varices. World J Gastroenterol. 2010 Feb 14; 16: (6)785-6.
    View PubMed
99. Ahn C, Ahn D. Randomized clinical trials in stroke research. J Investig Med. 2010 Feb; 58: (2)277-81.
    View PubMed
100. Ahn C, Hu F, Skinner CS, Ahn D. Effect of imbalance and intracluster correlation coefficient in cluster randomization trials with binary outcomes when the available number of clusters is fixed in advance. Contemp Clin Trials. 2009 Jul; 30: (4)317-20.
     View PubMed